Time in Therapeutic Range for Bivalirudin Among Pediatric Ventricular Assist Device Recipients

We report very good %TTR for bivalirudin both in the first 2 weeks post implant and this improved over the duration of support. Because %TTR reflects the degree of safety and efficacy in chronic anticoagulation, this relatively high %TTR among a diverse, often critically ill cohort suggests that bivalirudin may be a promising agent. Although this study was underpowered to comprehensively evaluate adverse events on bivalirudin, this represents an important next step for larger scale study.
Source: ASAIO Journal - Category: Medical Devices Tags: Pediatric Circulatory Support Source Type: research